These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36764305)

  • 21. The Effect of Low Glycemic Index and Glycemic Load Diets on Hepatic Fat Mass, Insulin Resistance, and Blood Lipid Panels in Individuals with Nonalcoholic Fatty Liver Disease.
    Parker A; Kim Y
    Metab Syndr Relat Disord; 2019 Oct; 17(8):389-396. PubMed ID: 31305201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.
    Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH
    J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gamma glutamyl transferase is an independent determinant for the association of insulin resistance with nonalcoholic fatty liver disease in Bangladeshi adults: Association of GGT and HOMA-IR with NAFLD.
    Hossain IA; Rahman Shah MM; Rahman MK; Ali L
    Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S25-9. PubMed ID: 26482965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocyte Mitochondrial Dynamics and Bioenergetics in Obesity-Related Non-Alcoholic Fatty Liver Disease.
    Legaki AI; Moustakas II; Sikorska M; Papadopoulos G; Velliou RI; Chatzigeorgiou A
    Curr Obes Rep; 2022 Sep; 11(3):126-143. PubMed ID: 35501558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
    Simon TG; Corey KE; Chung RT; Giugliano R
    Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?
    Shabani P; Naeimi Khaledi H; Beigy M; Emamgholipour S; Parvaz E; Poustchi H; Doosti M
    PLoS One; 2015; 10(3):e0118650. PubMed ID: 25767880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selenium and selenoprotein P in nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Goulas A; Duntas L
    Hormones (Athens); 2020 Mar; 19(1):61-72. PubMed ID: 31493247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling.
    Shabalala SC; Dludla PV; Mabasa L; Kappo AP; Basson AK; Pheiffer C; Johnson R
    Biomed Pharmacother; 2020 Nov; 131():110785. PubMed ID: 33152943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease.
    Parker R; Weston CJ; Miao Z; Corbett C; Armstrong MJ; Ertl L; Ebsworth K; Walters MJ; Baumart T; Newland D; McMahon J; Zhang P; Singh R; Campbell J; Newsome PN; Charo I; Schall TJ; Adams DH
    Am J Physiol Gastrointest Liver Physiol; 2018 Apr; 314(4):G483-G493. PubMed ID: 29420066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis.
    Kuraji R; Sekino S; Kapila Y; Numabe Y
    Periodontol 2000; 2021 Oct; 87(1):204-240. PubMed ID: 34463983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.
    Lim S; Taskinen MR; Borén J
    Obes Rev; 2019 Apr; 20(4):599-611. PubMed ID: 30589487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease.
    Rosso C; Mezzabotta L; Gaggini M; Salomone F; Gambino R; Marengo A; Saba F; Vanni E; Younes R; Saponaro C; Buzzigoli E; Caviglia GP; Abate ML; Smedile A; Rizzetto M; Cassader M; Gastaldelli A; Bugianesi E
    Hepatology; 2016 Jan; 63(1):107-16. PubMed ID: 26473614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first?
    Ahmed MH; Ali A
    Scand J Gastroenterol; 2014 May; 49(5):521-7. PubMed ID: 24646400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-invasive assessment of hepatic lipid subspecies matched with non-alcoholic fatty liver disease phenotype.
    Erickson ML; Haus JM; Malin SK; Flask CA; McCullough AJ; Kirwan JP
    Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1197-1204. PubMed ID: 31371265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease.
    Negi CK; Babica P; Bajard L; Bienertova-Vasku J; Tarantino G
    Metabolism; 2022 Jan; 126():154925. PubMed ID: 34740573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease.
    Ziolkowska S; Binienda A; Jabłkowski M; Szemraj J; Czarny P
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum interleukin-38 levels correlated with insulin resistance, liver injury and lipids in non-alcoholic fatty liver disease.
    Cao J; Hua L; Zhang S; Tang J; Ke F; Wu Z; Xue G
    Lipids Health Dis; 2022 Aug; 21(1):70. PubMed ID: 35948957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
    Zhuge B; Li G
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.